Sorry, you need to enable JavaScript to visit this website.

COVID-19 mRNA Vaccine BNT162b2

This medicinal product has been given authorisation for temporary supply by the UK Department of Health and Social Care and the Medicines & Healthcare products Regulatory Agency. It does not have a marketing authorisation, but this temporary authorisation grants permission for the medicine to be used for active immunization to prevent COVID-19 disease caused by SARS-CoV-2 virus in individuals aged 16 years of age and over.

As with any new medicine in the UK, this product will be closely monitored to allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.

Please click on the question above to see related content

How can I order the vaccine?

For Trusts and Primary Care Network (PCN) designated sites, details about the ordering process for COVID-19 vaccines can be found in the Standard Operating Procedures on the Specialist Pharmacy Service website.1

For COVID-19 Vaccination Centres, information on allocation and ordering COVID-19 vaccines can be found here.2

1: Specialist Pharmacy Service. COVID-19 Vaccines Dealing with delivery issues associated with the Covid-19 vaccines and consumables: Accessed February 2021

2: NHS England and NHS Improvement.COVID-19 Vaccination Centres: Operating Framework: Accessed February 2021.

How do I prepare and administer the vaccine?

The COVID-19 mRNA Vaccine BNT162b2 Reg 174 Information for UK Healthcare Professionals states the following in Section 4.2 Posology and method of administration:

Method of administration

Administer the COVID-19 mRNA Vaccine BNT162b2 intramuscularly in the deltoid muscle after dilution. 
After dilution, vials of COVID-19 mRNA Vaccine BNT162b2 contain six doses of 0.3 mL of vaccine. In order to extract six doses from a single vial, low dead-volume syringes and/or needles should be used. If standard syringes and needles are used, there may not be sufficient volume to extract a sixth dose from a single vial. Irrespective of the type of syringe and needle: 

  • Each dose must contain 0.3 mL of vaccine.   
  • If the amount of vaccine remaining in the vial cannot provide a full dose of 0.3 mL, discard the vial and any excess volume.  
  • Do not pool excess vaccine from multiple vials. 

Do not inject the vaccine intravascularly, subcutaneously or intradermally.  
Preparation: The multidose vial is stored frozen and must be thawed prior to dilution. 

Further detailed information on the preparation of the vaccine can be found in Section 4.2 of the COVID-19 mRNA Vaccine BNT162b2 Reg 174 Information for UK Healthcare Professionals.

Alternatively, for further information on this topic please use the search function above.